The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review
Open accessAbstract
BACKGROUND: Tuberculosis (TB) incidence and mortality are declining worldwide; however, poor detection of drug-resistant disease threatens to reverse current progress toward global TB control. Multiple, rapid molecular diagnostic tests have recently been developed to detect genetic mutations in Mycobacterium tuberculosis (Mtb) genes known to confer first-line drug resistance. Their utility, though, depends on the frequency and distribution of the resistance associated mutations in the pathogen population. Mutations associated with rifampicin resistance, one of the two first-line drugs, are well understood and appear to occur in a single gene region in >95% of phenotypically resistant isolates. Mutations associated with isoniazid, the other first-line drug, are more complex and occur in multiple Mtb genes. OBJECTIVES/METHODOLOGY: A systematic review of all published studies from January 2000 through August 2013 was conducted to quantify the frequency of the most common mutations associated with isoniazid resistance, to describe the frequency at which these mutations co-occur, and to identify the regional differences in the distribution of these mutations. Mutation data from 118 publications were extracted and analyzed for 11,411 Mtb isolates from 49 countries. PRINCIPAL FINDINGS/CONCLUSIONS: Globally, 64% of all observed phenotypic isoniazid resistance was associated with the katG315 mutation. The second most frequently observed mutation, inhA-15, was reported among 19% of phenotypically resistant isolates. These two mutations, katG315 and inhA-15, combined with ten of the most commonly occurring mutations in the inhA promoter and the ahpC-oxyR intergenic region explain 84% of global phenotypic isoniazid resistance. Regional variation in the frequency of individual mutations may limit the sensitivity of molecular diagnostic tests. Well-designed systematic surveys and whole genome sequencing are needed to identify mutation frequencies in geographic regions where rapid molecular tests are currently being deployed, providing a context for interpretation of test results and the opportunity for improving the next generation of diagnostics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R. (1994) · Science · doi:10.1126/science.8284673 · Cited by 1,389
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Lowrie, D., Colston, M. J., & Cole, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90417-f · Cited by 1,337
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299
Molecular genetic basis of antimicrobial agent resistance inMycobacterium tuberculosis: 1998 update
Ramaswamy, S., & Musser, J. M. (1998) · Tubercle and Lung Disease · doi:10.1054/tuld.1998.0002 · Cited by 1,089
Tiemersma, E. W., van der Werf, M. J., Borgdorff, M. W., Williams, B. G., & Nagelkerke, N. J. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017601 · Cited by 583 · cited 1×
“Suboptimal treatment and poor adherence to drug therapies contribute to resistance amplification; while lack of detection and subsequent inappropriate treatment increase the risk of direct transmission of drug-resistantMtb [5,8,9].”
BackgroundMechanisms of Drug Resistance in Mycobacterium tuberculosis
Heym, B., Philipp, W., & Cole, S. T. (1996) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-80166-2_3 · Cited by 379
Campbell, P. J., Morlock, G. P., Sikes, R. D., Dalton, T. L., Metchock, B., Starks, A. M., Hooks, D. P., Cowan, L. S., Plikaytis, B. B., & Posey, J. E. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01550-10 · Cited by 379
Multidrug-Resistant Mycobacterium tuberculosis: Molecular Perspectives
Rattan, A., Kalia, A., & Ahmad, N. (1998) · Emerging Infectious Diseases · doi:10.3201/eid0402.980207 · Cited by 355
Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid
Vilchèze, C., Wang, F., Arai, M., Hazbón, M. H., Colangeli, R., Kremer, L., Weisbrod, T. R., Alland, D., Sacchettini, J. C., & Jacobs, W. R. (2006) · Nature Medicine · doi:10.1038/nm1466 · Cited by 319
Mechanisms of Drug Resistance in Mycobacterium tuberculosis
Zhang, Y., Vilchèze, C., & Jacobs, W. R. (2004) · Tuberculosis and the Tubercle Bacillus · doi:10.1128/9781555817657.ch8 · Cited by 261
Georghiou, S. B., Magana, M., Garfein, R. S., Catanzaro, D. G., Catanzaro, A., & Rodwell, T. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033275 · Cited by 249
Self-citationIsoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report.
Middlebrook, G. (1954) · PubMed · doi:10.1164/art.1954.69.3.471 · Cited by 239
Impact of Bacterial Genetics on the Transmission of Isoniazid-Resistant Mycobacterium tuberculosis
Gagneux, S., Burgos, M. V., DeRiemer, K., Enciso, A., Muñoz, S., Hopewell, P. C., Small, P. M., & Pym, A. S. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020061 · Cited by 230
The Diagnosis and Therapy of Tuberculosis During the Past 100 Years
Mitchison, D. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200411-1603oe · Cited by 185
Sreevatsan, S., Pan, X., Zhang, Y., Deretic, V. P., & Musser, J. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.600 · Cited by 152
Mechanisms of Drug Resistance in Mycobacterium tuberculosis
Cole, S. T. (1994) · Immunobiology · doi:10.1016/s0171-2985(11)80466-3 · Cited by 138
Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis
Ahmad, S., & Mokaddas, E. M. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.07.010 · Cited by 128
Haas, W., Schilke, K., Brand, J., Amthor, B., Weyer, K., Fourie, P. B., Bretzel, G., Sticht-Groh, V., & Bremer, H. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1601 · Cited by 115
Molecular determinants of drug resistance in tuberculosis.
Riska, P. F., Jacobs, W. R., & Alland, D. (2000) · PubMed · Cited by 106
Predicting Extensively Drug-Resistant Mycobacterium tuberculosis Phenotypes with Genetic Mutations
Rodwell, T. C., Valafar, F., Douglas, J. T., et al. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.02701-13 · Cited by 106
Self-citationQuantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009
Jenkins, H. E., Zignol, M., & Cohen, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022927 · Cited by 103
Ando, H., Kondo, Y., Suetake, T., Toyota, E., Kato, S., Mori, T., & Kirikae, T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01691-09 · Cited by 91
Laurenzo, D., & Mousa, S. A. (2011) · Acta Tropica · doi:10.1016/j.actatropica.2011.04.008 · Cited by 88
Baker, L. V., Brown, T., Maxwell, O., Gibson, A. L., Fang, Z., Yates, M. D., & Drobniewski, F. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1455-1464.2005 · Cited by 78
Lin, S.-Y. G., Rodwell, T. C., Victor, T. C., Rider, E. C., Pham, L., Catanzaro, A., & Desmond, E. P. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01821-13 · Cited by 74
Self-citationNew and improved diagnostics for detection of drug-resistant pulmonary tuberculosis
O’Grady, J., Maeurer, M. J., Mwaba, P., Kapata, N., Bates, M., Höelscher, M., & Zumla, A. I. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283452346 · Cited by 72
Antitubercular Isoniazid and Drug Resistance of Mycobacterium tuberculosis — A Review
Scior, T., Morales, I. M., Garcés‐Eisele, S. J., Domeyer, D. M., & Laufer, S. (2002) · Archiv der Pharmazie · doi:10.1002/ardp.200290005 · Cited by 66
Lin, S.-Y. G., Probert, W. S., Lo, M. W., & Desmond, E. P. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.9.4204-4208.2004 · Cited by 66
Isoniazid Resistance and the Future of Drug-Resistant Tuberculosis
Cohen, T., Becerra, M. C., & Murray, M. B. (2004) · Microbial Drug Resistance · doi:10.1089/mdr.2004.10.280 · Cited by 56
Abate, G., Hoffner, S., Thomsen, V. Ø., & Miörner, H. (2001) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/pl00011272 · Cited by 54
Advances in rapid diagnosis of tuberculosis disease and anti-tuberculous drug resistance
Alcaide, F., & Coll, P. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70016-7 · Cited by 43
Tuberculose resistente: revisão molecular
Rossetti, M. L. R., Valim, A. R. D. M., Silva, M. S. N., & Rodrigues, V. D. F. S. (2002) · Revista de Saúde Pública · doi:10.1590/s0034-89102002000400021 · Cited by 42
Detecting Drug-Resistant Tuberculosis: The Importance of Rapid Testing
Hoek, K. G. P., Rie, A. V., van Helden, P. D., Warren, R. M., & Victor, T. C. (2011) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256410 · Cited by 23
Lessells, R. J., Cooke, G., Newell, M., & Godfrey‐Faussett, P. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir412 · Cited by 23
Scaling up tuberculosis culture services: a precautionary note.
Urbanczik, R., & Rieder, H. L. (2009) · PubMed · Cited by 10
Cited by
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Recent updates on drug resistance in Mycobacterium tuberculosis
Singh, R., Dwivedi, S. P., Gaharwar, U. S., Meena, R., Rajamani, P., & Prasad, T. (2020) · Journal of Applied Microbiology · doi:10.1111/jam.14478 · Cited by 337
Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis
Unissa, A. N., Subbian, S., Hanna, L. E., & Selvakumar, N. (2016) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2016.09.004 · Cited by 300
Al-Obaid, I., Asadzadeh, M., Ahmad, S., Alobaid, K., Alfouzan, W., Bafna, R., Emara, M., & Joseph, L. (2022) · Journal of Fungi · doi:10.3390/jof8030267 · Cited by 39
Metadata
- Authors
- Seifert, M., Catanzaro, D., Catanzaro, A., & Rodwell, T. C.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-03-23
- Volume
- 10
- Issue
- 3
- Pages
- e0119628
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2010351435
- Cited by
- 326
- References
- 35
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.